Synthetic Biologics, Inc. SYN Income Statement

Synthetic biologics, inc. (SYN)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Operating Costs and Expenses:
License revenue, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Laboratory revenues, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total Revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
General and administrative
4,819	4,580	4,498	4,874	5,261	5,727	6,553	6,784	6,997	7,467	8,914	9,304	9,807	10,143	9,203	8,712	8,787	8,074	7,398	7,012	6,604	6,013	5,716	6,388	5,832	5,832	5,565	4,748	4,666	5,012	3,966	3,475	2,823	2,588	2,940	3,021	0	0	0
Research and development
10,300	11,083	11,212	9,914	10,892	11,844	13,545	14,836	16,095	18,784	21,756	24,680	27,013	29,109	31,238	34,223	34,567	32,906	29,290	22,937	18,266	14,489	11,958	9,740	8,106	6,507	14,387	13,675	13,019	12,287	4,235	3,761	3,495	3,340	1,030	1,167	0	0	0
Costs of laboratory services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total Operating Costs and Expenses
15,119	15,663	15,710	14,788	16,153	17,571	20,098	21,620	23,092	26,251	30,670	33,984	36,820	39,252	40,441	42,935	43,354	40,980	36,688	29,949	24,870	20,502	17,674	16,128	13,938	12,339	19,952	18,423	17,685	17,299	8,201	7,236	6,318	5,928	4,163	4,513	0	0	0
Loss from Operations
-15,119	-15,663	-15,710	-14,788	-16,153	-17,571	-20,098	-21,620	-23,092	-26,251	-30,670	-33,984	-36,820	-39,252	-40,441	-42,935	-43,354	-40,980	-36,688	-29,949	-24,870	-20,502	-16,766	0	0	-	0	-	-	-	-	-	-	-	-	-	-	0	0
Loss from Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-8,201	-7,236	-6,318	-5,928	0	0	0	-	-
Other Income :
Change in fair value of warrant liability
-	-	-19	-645	-	-4,083	-12,645	-6,927	-8,303	-10,738	-9,888	-15,646	-17,000	-11,412	-3,776	-7,251	157	3,811	3,286	7,427	3,532	-620	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-12	-99	-75	-22	-18	0	0	0	-	-	-	-	-	-
Warrant expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,492	0	0	0	-	-
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	242	0	0	0	-	-
Warrant expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Change in fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Interest income
277	283	263	176	102	67	35	34	29	21	7	4	37	37	37	38	6	6	6	5	3	3	3	13	23	33	65	54	44	33	0	0	0	-	-	-	-	0	-
Loss on the sale of equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-
Other income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	61	61	0	0	0
Total Other Income
277	283	282	821	1,530	4,150	12,680	6,961	8,332	10,759	9,895	15,650	17,037	11,449	3,813	7,289	-151	-3,805	-3,280	-7,422	-3,434	718	145	141	10	21	-34	-21	22	15	3	-166	-934	-1,698	-1,678	-1,513	0	0	0
Loss from Continuing Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-17,284	-8,198	-7,402	-7,252	-7,626	0	0	0	-	-
Income from Discontinued Operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	216	11	47	89	-523	0	0	0	-	-
Net Loss
-14,842	-15,380	-15,428	-13,967	-14,623	-13,421	-7,418	-14,659	-14,760	-15,492	-20,775	-18,334	-19,783	-27,803	-36,628	-35,646	-43,505	-44,785	-39,968	-37,371	-28,304	-19,784	-17,529	-15,987	-13,928	-12,318	0	0	0	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Non-controlling Interest
-87	-77	-91	-70	-60	-54	-74	-73	-116	-318	-377	-505	-527	-548	-766	-1,363	-1,281	-1,048	-733	0	0	0	-1	-1	-1	-1	0	0	0	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries
-14,755	-15,303	-15,337	-13,897	-14,563	-13,367	-7,344	-14,586	-14,644	-15,174	-20,398	-17,829	-19,256	-27,255	-35,862	-34,283	-42,224	-43,737	-39,235	-37,371	-28,304	-19,784	-17,528	-15,986	-13,927	-12,317	-20,159	-18,721	-18,096	-17,068	-8,187	-7,355	-7,163	-8,149	-5,696	-3,619	0	0	0
Preferred Stock Dividends, Income Statement Impact
-	-	-	-	-	-	-	-	-	73	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Common Stockholders
-15,535	-16,076	-27,850	-26,338	-26,887	-25,291	-7,586	-21,668	-21,665	-22,136	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss Per Share - Basic and Dilutive (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.08	-0.07	-	-0.08	-0.06	-0.05	-0.34	-0.05	-0.05	-0.06	-0.08	-0.04	-0.06	-0.09	-	-
Discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.01	0.00	0.00	0.02	-0.02	0.00	0.00	0.00	-	-
Net Loss Per Share - Basic and Dilutive
-0.20	-0.19	-0.31	-0.23	-0.25	-1.32	-0.93	-1.16	-0.65	-1.28	-4.90	-0.03	-0.02	-0.02	-0.09	-0.06	-0.12	-	-	-	-0.17	-	-	-0.08	-0.07	-0.08	-0.08	-0.06	-0.05	-0.35	-0.05	-0.05	-0.04	-0.10	-0.04	-0.06	-0.09	-0.03	-
Weighted average number of shares outstanding during the period - Basic and Dilutive
17,093	16,825	16,805	16,465	15,656	13,544	4,028	3,683	3,673	-229,904	3,665	123,005	117,447	-	91,441	-	90,826	-	-	-	72,673	-	-	58,453	58,324	48,761	44,654	44,654	44,601	41,188	33,383	33,011	32,003	-	28,089	27,885	-	-	-
Net Loss Per Share - Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.08	-0.19	-	-	-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05
Net Loss Per Share - Dilutive
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.10	-	-	-0.12	-0.19	-	-	-0.08	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.05
Weighted average number of shares outstanding during the period - Basic
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91,015	-	-	85,974	72,736	-	-	58,453	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,706
Weighted average number of shares outstanding during the period - Dilutive
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	93,930	-	-	87,585	72,736	-	-	58,453	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,883
Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25,220	23,003	-
Series B Preferred Stock [Member]
Net Loss Attributable to Non-controlling Interest
0	-	0	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries
0	-	0	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred Stock Dividends, Income Statement Impact
531	525	12,266	12,196	12,079	11,681	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Series A Preferred Stock [Member]
Preferred Stock Dividends, Income Statement Impact
201	200	204	202	202	200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-